CRISPR Therapeutics AG Insider Trading for March 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in CRISPR Therapeutics AG.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in CRISPR Therapeutics AG for March 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | M | 44.67 | 12,000 | 536,040 | 43,000 | |
| Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | M | 40.87 | 20,000 | 817,400 | 25,000 | |
| Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | M | 29.87 | 10,000 | 298,700 | 10,000 | |
| Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | M | 51.49 | 22,000 | 1,132,780 | 38,000 | |
| Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | M | 17.66 | 12,000 | 211,920 | 3,000 | |
| Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | M | 14.43 | 12,000 | 173,160 | 2,666 | |
| Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 126.97 | 12,000 | 1,523,640 | 1,050 | 13.1 K to 1.1 K (-91.95 %) |
| Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 128.20 | 88,000 | 11,281,600 | 13,050 | 101.1 K to 13.1 K (-87.09 %) |
| Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 17.66 | 12,000 | 211,920 | 101,050 | 89.1 K to 101.1 K (+13.48 %) |
| Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 14.43 | 12,000 | 173,160 | 89,050 | 77.1 K to 89.1 K (+15.57 %) |
| Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 40.87 | 20,000 | 817,400 | 77,050 | 57.1 K to 77.1 K (+35.06 %) |
| Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 29.87 | 10,000 | 298,700 | 57,050 | 47.1 K to 57.1 K (+21.25 %) |
| Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 51.49 | 22,000 | 1,132,780 | 47,050 | 25.1 K to 47.1 K (+87.82 %) |
| Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 44.67 | 12,000 | 536,040 | 25,050 | 13.1 K to 25.1 K (+91.95 %) |
| Mar 24 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 134.93 | 300 | 40,478 | 30,375 | 30.7 K to 30.4 K (-0.98 %) |
| Mar 24 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 134.33 | 5,237 | 703,495 | 30,675 | 35.9 K to 30.7 K (-14.58 %) |
| Mar 24 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 133.28 | 9,334 | 1,244,070 | 35,912 | 45.2 K to 35.9 K (-20.63 %) |
| Mar 24 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 132.53 | 6,090 | 807,092 | 45,246 | 51.3 K to 45.2 K (-11.86 %) |
| Mar 24 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 131.14 | 2,400 | 314,741 | 51,336 | 53.7 K to 51.3 K (-4.47 %) |
| Mar 24 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 130.42 | 3,413 | 445,112 | 53,736 | 57.1 K to 53.7 K (-5.97 %) |
| Mar 24 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 129.36 | 3,600 | 465,678 | 57,149 | 60.7 K to 57.1 K (-5.93 %) |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 0.00 | 9,000 | 0 | 9,000 | |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 133.88 | 25,360 | 3,395,197 | 25,360 | |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Payment of Exercise | F | 124.15 | 1,352 | 167,851 | 1,891 | 3.2 K to 1.9 K (-41.69 %) |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Buy | M | 0.00 | 2,833 | 0 | 3,243 | 410 to 3.2 K (+690.98 %) |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 0.00 | 36,000 | 0 | 36,000 | |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 133.88 | 100,000 | 13,388,000 | 100,000 | |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 124.15 | 5,526 | 686,053 | 188,498 | 194 K to 188.5 K (-2.85 %) |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 0.00 | 11,833 | 0 | 194,024 | 182.2 K to 194 K (+6.49 %) |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | A | 0.00 | 12,000 | 0 | 12,000 | |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | A | 133.88 | 33,334 | 4,462,756 | 33,334 | |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Payment of Exercise | F | 124.15 | 2,141 | 265,805 | 13,050 | 15.2 K to 13.1 K (-14.09 %) |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 0.00 | 4,583 | 0 | 15,191 | 10.6 K to 15.2 K (+43.20 %) |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Option Exercise | A | 0.00 | 9,000 | 0 | 9,000 | |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Option Exercise | A | 133.88 | 25,360 | 3,395,197 | 25,360 | |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Payment of Exercise | F | 124.15 | 1,353 | 167,975 | 23,911 | 25.3 K to 23.9 K (-5.36 %) |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Buy | M | 0.00 | 2,833 | 0 | 25,264 | 22.4 K to 25.3 K (+12.63 %) |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Option Exercise | A | 0.00 | 9,000 | 0 | 9,000 | |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Option Exercise | A | 133.88 | 23,334 | 3,123,956 | 23,334 | |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Payment of Exercise | F | 124.15 | 2,141 | 265,805 | 38,304 | 40.4 K to 38.3 K (-5.29 %) |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Buy | M | 0.00 | 4,583 | 0 | 40,445 | 35.9 K to 40.4 K (+12.78 %) |
| Mar 09 2021 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Payment of Exercise | F | 114.65 | 1,585 | 181,720 | 35,862 | 37.4 K to 35.9 K (-4.23 %) |
| Mar 09 2021 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Buy | M | 0.00 | 3,333 | 0 | 37,447 | 34.1 K to 37.4 K (+9.77 %) |
| Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 565 | 0 | 60,749 | 60.2 K to 60.7 K (+0.94 %) |
| Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 4,012 | 0 | 0 | 4 K to 0 (-100.00 %) |
| Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 4,012 | 0 | 4,012 | 0 to 4 K |
| Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 18,574 | 0 | 44,295 | 62.9 K to 44.3 K (-29.54 %) |
| Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 12,648 | 0 | 60,184 | 47.5 K to 60.2 K (+26.61 %) |
| Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 56,056 | 0 | 0 | 56.1 K to 0 (-100.00 %) |
| Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 1,755 | 0 | 56,056 | 54.3 K to 56.1 K (+3.23 %) |
| Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 8,126 | 0 | 18,457 | 26.6 K to 18.5 K (-30.57 %) |
| Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 1,585 | 0 | 54,301 | 52.7 K to 54.3 K (+3.01 %) |
| Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 7,341 | 0 | 16,625 | 24 K to 16.6 K (-30.63 %) |
| Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 52,716 | 0 | 52,716 | 0 to 52.7 K |
| Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 244,056 | 0 | 581,999 | 826.1 K to 582 K (-29.54 %) |
| Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 130.25 | 798 | 103,940 | 182,191 | 183 K to 182.2 K (-0.44 %) |